Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 21, 2026 09:42 ET | Source: Research and Markets

Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035

Dublin, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Regional Analysis, 2025-2035" has been added to ...
January 13, 2026 07:05 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Boehringer launches clinical trial exploring interleukin-11’s potential to go beyond slowing IPF and restore lung function.
January 08, 2026 08:00 ET | Source: GRI Bio, Inc.

GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621

New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE...
January 08, 2026 05:00 ET | Source: AgomAb Therapeutics N.V.

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.
December 10, 2025 16:05 ET | Source: GRI Bio, Inc.

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used...
November 18, 2025 10:06 ET | Source: Research and Markets

Idiopathic Pulmonary Fibrosis Research Report 2025-2035: Market Led by Roche, Pliant Therapeutics, Bristol-Myers Squibb, and Vicore as Next-Gen Antifibrotics and Targeted Therapies Drive Innovation

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Idiopathic Pulmonary Fibrosis Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been...
October 22, 2025 06:12 ET | Source: Boehringer Ingelheim Limited

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

"Not intended for US or UK audiences."Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the absolute change...
October 15, 2025 07:00 ET | Source: Transpire Bio

Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases

Transpire Bio today announced that the U.S. FDA has granted orphan drug designation (ODD) for two of its products in development.
October 09, 2025 06:05 ET | Source: Boehringer Ingelheim Limited

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is based on results from two...
September 29, 2025 02:05 ET | Source: Boehringer Ingelheim Limited

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without...